Expression of activated N-ras in a primary melanoma cell line counteracts growth inhibition by transforming growth factor-β

Journal of Investigative Dermatology

Volumn 114, Issue 6, 2000, Pages 1200-1204

  Shellman, Yiqun G ^a   Chapman, James T ^a   Fujita, Mayumi ^a   Norris, David A ^a,b,c   Maxwell, Ian H ^a,b,d  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; LUCIFERASE; RETINOBLASTOMA PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL CYCLE; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MELANOMA CELL; ONCOGENE N RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0034044890     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2000.00988.x     Document Type: Article

References (39)

1. Albino AP, Nanus DM, Mentle IR, Cordon-Cardo C, McNutt NS, Bressler J, Andreeff M: Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Ontogene 4:1363-1374, 1989
2. Alexandrow MG, Moses HL: Transforming growth factor beta and cell cycle regulation. Cancer Res 55:1452-1457, 1995
3. Attisano L, Carcamo J, Ventura F, Weis FM, Massague J, Wrana JL: Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 75:671-680, 1993
4. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP: Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 102:285-290, 1994
5. Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 49:4682-4689, 1989
6. Buchkovich K, Duffy LA, Harlow E: The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58:1097-1105, 1989
7. Chen PL, Scully P, Shew JY, Wang JY, Lee WH: Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58:1193-1198, 1989
8. Chin L, Pomerantz J, Polsky D, et al: Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 11:2822-2834, 1997
9. Chin L, Tam A, Pomerantz J, et al: Essential role for oncogenic Ras in tumour maintenance. Nature 400:468-472, 1999
10. Cobrinik D, Dowdy SF, Hinds PW, Mittnacht S, Weinberg RA: The retinoblastoma protein and the regulation of cell cycling. Trends Biochem Sci 17:312-315, 1992
11. DeCaprio JA, Ludlow JW, Lynch D, et al: The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 58:1085-1095, 1989
12. van Elsas A, Zerp SF, van der Flier S, et al: Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 149:883-893, 1996
13. Filmus J, Zhao J, Buick RN: Overexpression of H-ras oncogene induces resistance to the growth-inhibitory action of transforming growth factor beta-1 (TGF-beta 1) and alters the number and type of TGF-beta 1 receptors in rat intestinal epithelial cell clones. Oncogene 7:521-526, 1992
14. Florenes VA, Bhattacharya N, Bani MR, Ben-David Y, Kerbel RS, Slingerland JM: TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1. Oncogene 13:2447-2457, 1996
15. Fujita M, Norris DA, Yagi H, et al: Overexpression of mutant ras in human melanoma increases invasiveness, proliferation and anchorage-independent growth in vitro and induces tumour formation and cachexia in vivo. Melanoma Res 9:279-291, 1999
16. Fynan TM, Reiss M: Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncol 4:493-540, 1993
17. Graulich W, Nettelbeck DM, Fischer D, Kissel T, Muller R: Cell type specificity of the human endoglin promoter. Gene 227:55-62, 1999
18. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371:257-261, 1994
19. Herlyn M, Thurin J, Balaban G, et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 45:5670-5676, 1985
20. Herlyn M, Clark WH, Rodeck U, Mancianti ML, Jambrosic J, Koprowski H: Biology of tumor progression in human melanocytes. Lab Invest 56:461-474, 1987
21. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA: Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993-1006, 1992
22. Houck KA, Michalopoulos GK, Strom SC: Introduction of a Ha-ras oncogene into rat liver epithelial cells and parenchymal hepatocytes confers resistance to the growth inhibitory effects of TGF-beta. Oncogene 4:19-25, 1989
23. Howe PH, Dobrowolski SF, Reddy KB, Stacey DW: Release from G1 growth arrest by transforming growth factor beta 1 requires cellular ras activity. J Biol Chem 268:21448-21452, 1993
24. Jafari M, Papp T, Kirchner S, Diener U, Henschler D, Burg G, Schiffmann D: Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J Cancer Res Clin Oncol 121:23-30, 1995
25. Jiveskog S, Ragnarsson-Olding B, Platz A, Ringborg U: N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol 111:757-761, 1998
26. Kerbel RS, Kobayashi H, Graham CH, Lu C: Analysis and significance of the malignant "eclipse" during the progression of primary cutaneous human melanomas. J Invest Dermatol Symp Proc 1:183-187, 1996
27. Krasagakis K, Garbe C, Zouboulis CC, Orfanos CE: Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res 139:169-182, 1995
28. Kretzschmar M, Doody J, Timokhina I, Massague J: A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev 13:804-816, 1999
29. Macara IG, Lounsbury KM, Richards SA, McKiernan C, Bar-Sagi D: The Ras superfamily of GTPases. FASEB J 10:625-630, 1996
30. Maxwell IH, Maxwell F: Electroporation of mammalian cells with a firefly luciferase expression plasmid: kinetics of transient expression differ markedly among cell types. DNA 7:557-562, 1988
31. McCormick F, Wittinghofer A: Interactions between Ras proteins and their effectors. Curr Opin Biotechnol 7:449-456, 1996
32. Polyak K: Negative regulation of cell growth by TGF beta. Biochem Biophys Acta 1242:185-199, 1996
33. Reynisdottir I, Polyak K, lavarone A, Massague J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev' 9:1831-1845, 1995
34. Rodeck U, Bossler A, Graeven U, Fox FE, Nowell PC, Knahbe C, Kari C: Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 54:575-581, 1994
35. Rodeck U, Nishiyama T, Mauviel A: Independent regulation of growth and SMAD-mediated transcription by transforming growth factor beta in human melanoma cells. Cancer Res 59:547-550, 1999
36. Satyamoorthy K, DeJesus E, Linnenbach AJ, et al: Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 7 (Suppl. 2):S35-S42, 1997
37. Sporn MB, Roberts AB: Autocrine growth factors and cancer. Nature 313:745-747, 1985
38. Wrana J, Pawson T: Signal transduction. Mad about SMADs. Nature 388:28-29, 1997
39. Wrana JL, Attisano L, Carramo J, et al: TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71:1003-1014, 1992